We produce institutional quality equity research on small/midcap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.
10
Research Clients
280
Reports published
10k+
Readers in database
4 SPLs signed YTD; now 15 in total. 3 most recent ( $CELU $SANA $NKTX) not yet included in potential >$950m of pre-commercial milestones. Progress at @MaxCyte_info's partners shld build a meaningful milestone stack mid-term. $MXCT Q3 to report Nov 10. https://www.trinitydelta.org/companies/maxcyte/
A 4th formulation development collaboration secured by @arecor_ltd so far in 2021, reinforcing broad industry interest in its #formulation expertise & #Arestat tech platforms $AREC.L
Global #savolitinib development continues to progress with @hutchmed & @AstraZeneca initiating the Phase III SAMETA combo trial + Imfinzi in #PRCC $AZN $HCM
R&D KOL event externally validates the quality of @RedxPharma #MedicinalChemistry expertise in solving druggability issues. Ph I data so far confirms promising safety & PK profiles of lead internal assets RXC004 (#Cancer ) & RXC007 (#fibrosis). $REDX.L https://www.trinitydelta.org/companies/redx-pharma/
Progress on multiple fronts at #AGL. Potential Q421 catalysts include: FDA approval of @Parsortix, clinical #ovariancancer LDT data, & US/UK clinical labs accreditation driving pharma service revenues, & acting as demonstrators & accelerators. $AGL.L https://www.trinitydelta.org/companies/angle/
Foundations established for both @avacta businesses. With 1st shipments of @AvactaDx's #COVID #LFT attention now shifts to commercial execution. But Therapeutics, now clinical-stage, will be longer-term value driver. H121 cash runs thru to 2023 $AVCT.L https://www.trinitydelta.org/companies/avacta/
Please sign up here to be added to our distribution database
';